Literature DB >> 9637275

Radionuclide cancer therapy.

C A Hoefnagel1.   

Abstract

Therapeutic nuclear medicine is rapidly developing as an additional treatment modality in oncology. Its unique characteristics are the systemic, yet selective delivery of radiation doses in target tissues, its non-invasiveness, the relative lack of immediate and late side effects, and the advantage that uptake and retention in the tumor can be pre-assessed by tracer studies. Many different tumor seeking radiopharmaceuticals are being used for therapy by different routes and a variety of targeting mechanisms. The current clinical role of radionuclide therapy is briefly reviewed, as well as more general aspects and considerations, such as mechanisms for tumor targeting, the choice of radionuclide labels, radiopharmacy, drug delivery, radiation protection, dosimetry and toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637275     DOI: 10.1007/bf03164831

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  6 in total

Review 1.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

2.  RNA Nanoparticles Derived from Three-Way Junction of Phi29 Motor pRNA Are Resistant to I-125 and Cs-131 Radiation.

Authors:  Hui Li; Piotr G Rychahou; Zheng Cui; Fengmei Pi; B Mark Evers; Dan Shu; Peixuan Guo; Wei Luo
Journal:  Nucleic Acid Ther       Date:  2015-05-27       Impact factor: 5.486

3.  153Sm and 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms.

Authors:  Fernanda Marques; Krassimira P Guerra; Lurdes Gano; Judite Costa; M Paula Campello; Luís M P Lima; Rita Delgado; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2004-08-28       Impact factor: 3.358

4.  Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study.

Authors:  T Aktoz; G Durmus-Altun; U Usta; N Torun; A Ergulen; I H Atakan
Journal:  Hippokratia       Date:  2012-01       Impact factor: 0.471

Review 5.  Lipid- and polymer-based nanostructures for cancer theranostics.

Authors:  Brian T Luk; Ronnie H Fang; Liangfang Zhang
Journal:  Theranostics       Date:  2012-12-10       Impact factor: 11.556

6.  Targeted radionuclide therapy.

Authors:  Devrim Ersahin; Indukala Doddamane; David Cheng
Journal:  Cancers (Basel)       Date:  2011-10-11       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.